药物相关性颌骨坏死非手术治疗的研究进展

doi:10.12337/zgkqjxjyzz.2025.05.004

中国口腔医学继续教育杂志 ›› 2025, Vol. 28 ›› Issue (5): 322-330.DOI: 10.12337/zgkqjxjyzz.2025.05.004

药物相关性颌骨坏死非手术治疗的研究进展

张逸云, 康非吾, 张雪明^*

同济大学口腔医学院,上海市同济口腔医院口腔颌面外科,上海牙组织修复与再生工程技术研究中心

出版日期:2025-09-30 发布日期:2025-09-30
通讯作者: ^* 张雪明,联系方式：（021）66315175,电子邮箱：zhangxm@tongji.edu.cn,通讯地址：上海市延长中路399号,200072
基金资助:
上海市东方英才计划拔尖项目（项目编号：BJWS2024018）

Research Advances in Non-Surgical Management of Medication-Related Osteonecrosis of the Jaw

Yiyun Zhang, Feiwu Kang, Xueming Zhang^*

Stomatological Hospital and Dental School of Tongji University, Department of Oral and Maxillofacial Surgery, The Affiliated Stomatology Hospital of Tongji University, Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, P.R. China

Online:2025-09-30 Published:2025-09-30
Contact: Xueming Zhang. Tel: (021)66315175. Emai: zhangxm@tongji.edu.cn. Address: No. 399, Yanchangzhong Road, Shanghai 200072, P.R. China.

摘要/Abstract

摘要： 药物相关性颌骨坏死是抗骨吸收药物及抗血管生成剂治疗引发的严重口腔并发症。当前临床管理面临显著挑战,相当数量患者常存在手术禁忌证,亟需探索有效的非手术治疗策略, 以减轻症状、改善生活质量,并开发辅助疗法以降低复发率、优化预后。本文系统评述药物相关性颌骨坏死非手术治疗领域的最新进展,聚焦药物治疗（特立帕肽、己酮可可碱等）和物理疗法（高压氧、臭氧等）和干细胞、外泌体等疗法在解决上述关键临床问题中的研究现状、疗效证据与转化潜力。

Abstract: Drug-related osteonecrosis of the jaw is a severe oral complication caused by anti-resorptive drugs and anti-angiogenic agents. Current clinical management faces significant challenges, with a considerable proportion of patients often having surgical contraindications. There is an urgent need to explore effective non-surgical treatment strategies to alleviate symptoms, improve quality of life, and develop adjunct therapies to reduce recurrence rates and optimize prognosis. This article systematically reviews the latest advancements in non-surgical treatments for drug-related osteonecrosis of the jaw, focusing on the research status, efficacy evidence, and translational potential of pharmacological therapies (such as teriparatide and pentoxyfilline), physical therapies (including hyperbaric oxygen and ozone), as well as stem cell and exosome-based therapies in addressing these critical clinical issues.

Key words: bisphosphonate-associated osteonecrosis of the jaw, medication-related osteonecrosis of the jaw, teriparatide, pentoxifylline, mesenchymal stem cells

张逸云, 康非吾, 张雪明. 药物相关性颌骨坏死非手术治疗的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 322-330.

Yiyun Zhang, Feiwu Kang, Xueming Zhang. Research Advances in Non-Surgical Management of Medication-Related Osteonecrosis of the Jaw[J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 322-330.

参考文献

[1] 何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21(4):313-325.
[2] Ruggiero SL, Dodson TB, Aghaloo T, et al.American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update[J]. J Oral Maxillofac Surg, 2022, 80(5): 920-943.
[3] Anastasilakis AD, Pepe J, Napoli N, et al.Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS[J]. J Clin Endocrinol Metab, 2022, 107(5):1441-1460.
[4] Jiang A, Zhang Z, Qiu X, et al.Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies[J]. Arch Toxicol, 2024, 98(3):689-708.
[5] Yarom N, Shapiro CL, Peterson DE, et al.Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline[J]. J Clin Oncol, 2019, 37(25):2270-2290.
[6] 孙国文, 田美. 药物相关性颌骨坏死不同阶段治疗方法述评[J]. 口腔颌面外科杂志, 2022, 32(3):135-143.
[7] Girotra M, Rubin MR, Bilezikian JP.The use of parathyroid hormone in the treatment of osteoporosis[J]. Rev Endocr Metab Disord, 2006, 7(1-2):113-121.
[8] Beaudart C, Veronese N, Douxfils J, et al.PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis[J]. Osteoporos Int, 2025, 36(6): 951-967.
[9] Guyer L, Lehmann O, Wenger M, et al.Long-term impact of teriparatide on bone mineral density, trabecular bone score, and fracture risk relative to total hip T-score: A two-decade, registry-based cohort study[J]. Bone, 2025, 195:117445.
[10] Harper RP, Fung E.Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)][J]. J Oral Maxillofac Surg, 2007, 65(3):573-580.
[11] Ohbayashi Y, Miyake M, Sawai F, et al.Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(4):e31-e37.
[12] Lau AN, Adachi JD.Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy[J]. J Rheumatol, 2009, 36(8):1835-1837.
[13] Lee JJ, Cheng SJ, Jeng JH, et al.Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy[J]. Head Neck, 2011, 33(9):1366-1371.
[14] Singh A, Chung K, Huryn JM, et al.Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2025, 140(3):e59-e63.
[15] Cheung A, Seeman E.Teriparatide therapy for alendronate-associated osteonecrosis of the jaw[J]. N Engl J Med, 2010, 363(25):2473-2474.
[16] Doh RM, Park HJ, Rhee Y, et al.Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants[J]. Implant Dent, 2015, 24(2):222-226.
[17] Neuprez A, Rompen E, Crielaard JM, et al.Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient[J]. Calcif Tissue Int, 2014, 95(1):94-96.
[18] Mohamed MM, Gunasekera WM, Glew D, et al.Teriparatide therapy for medication-related osteonecrosis of the jaw: case report and literature review[J]. Clin Med (Lond), 2022, 22(Suppl 4):20-21.
[19] Yoshiga D, Yamashita Y, Nakamichi I, et al.Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws[J]. Osteoporos Int, 2013, 24(8):2365-2369.
[20] Sim IW, Borromeo GL, Tsao C, et al.Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial[J]. J Clin Oncol, 2020, 38(26):2971-2980.
[21] Park JH, Park W, Nguyen LP, et al.Treatment period and changes in bone markers according to the application of teriparatide in treating medication-related osteonecrosis of the jaw[J]. BMC Oral Health, 2025, 25(1):528.
[22] Krege JH, Gilsenan AW, Komacko JL, et al.Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates[J]. JBMR Plus, 2022, 6(9):e10665.
[23] Gilsenan A, Midkiff K, Harris D, et al.Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study[J]. J Bone Miner Res, 2020, 36(2):244-251.
[24] Khoury W, Trus R, Chen X, et al.Parsimonious Effect of Pentoxifylline on Angiogenesis: A Novel Pentoxifylline-Biased Adenosine G Protein-Coupled Receptor Signaling Platform[J]. Cells, 2023, 12(8):1199.
[25] Owosho AA, Estilo CL, Huryn JM, et al.Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(4):455-459.
[26] Słowik Ł, Totoń E, Nowak A, et al.Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol[J]. J Clin Med, 2025, 14(3):974.
[27] Magalhães JMI, da Motta Silveira FM, Regueira LS, et al. Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series[J]. Support Care Cancer, 2023, 31(8):462.
[28] De Morais RPL, De Aguiar AWPB, de Hora Sales PH, et al. Is the use of Pentoxifylline and Tocopherol effective in the treatment of Osteoradionecrosis of the jaws or for the treatment of medication osteonecrosis of the jaw? An overview[J]. J Stomatol Oral Maxillofac Surg, 2024, 125(5 supple 1):101959.
[29] Brunner C, Arvandi M, Marth C, et al.Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study[J]. J Clin Oncol, 2025, 43(2):180-188.
[30] Playdon MC, Ziegler RG, Sampson JN, et al.Nutritional metabolomics and breast cancer risk in a prospective study[J]. Am J Clin Nutr, 2017, 106(2):637-649.
[31] De Oliveira VA, Oliveira IKF, Pereira IC, et al.Consumption and supplementation of vitamin E in breast cancer risk, treatment, and outcomes: A systematic review with meta-analysis[J]. Clin Nutr ESPEN, 2023, 54: 215-226.
[32] Nava-Tapia DA, Román-Justo NY, Cuenca-Rojo A, et al.Exploring the potential of tocopherols: mechanisms of action and perspectives in the prevention and treatment of breast cancer[J]. Med Oncol, 2024, 41(9):208.
[33] Ortega MA, Fraile-Martinez O, García-Montero C, et al.A General Overview on the Hyperbaric Oxygen Therapy: Applications, Mechanisms and Translational Opportunities[J]. Medicina (Kaunas), 2021, 57(9):864.
[34] Silva ML, Tasso L, Azambuja AA, et al.Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy—histomorphometric and immunohistochemical analysis[J]. Clin Oral Investig, 2017, 21(1):199-210.
[35] Liu SS, Lin TY, Fu E, et al.Immediate hyperbaric oxygen after tooth extraction ameliorates bisphosphonate-related osteonecrotic lesion in rats[J]. J Periodontol, 2019, 90(12): 1449-1456.
[36] Watanabe T, Asai K, Fukuhara S, et al.Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage[J]. PLoS One, 2021, 16(1):e0244859.
[37] Pereira-Silva M, Hadad H, de Jesus LK, et al. Ozone therapy effect in medication-related osteonecrosis of the jaw as prevention or treatment: microtomographic, confocal laser microscopy and histomorphometric analysis[J]. Clin Oral Investig, 2024, 28(2):151.
[38] Delanora LA, de Lima Neto TJ, da Rocha TE, et al. Systemic Ozone Therapy Improves Oral Hard and Soft Tissue Healing in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Study in Senescent Female Rats[J]. Biomedicines, 2025, 13(5):1248.
[39] Di Fede O, Del Gaizo C, Panzarella V, et al.Ozone Infiltration for Osteonecrosis of the Jaw Therapy: A Case Series[J]. J Clin Med, 2022, 11(18):5307.
[40] Di Fede O, La Mantia G, Del Gaizo C, et al.Reduction of MRONJ risk after exodontia by virtue of ozone infiltration: A randomized clinical trial[J]. Oral Dis, 2024, 30(8):5183-5194.
[41] Berni M, Brancato AM, Torriani C, et al.The Role of Low-Level Laser Therapy in Bone Healing: Systematic Review[J]. Int J Mol Sci, 2023, 24(8):7094.
[42] Ayhan M, Gedik B, Kalelioglu EE, et al.Comparison of the Effects of Four Laser Wavelengths on Medication-Related Osteonecrosis of the Jaw (MRONJ) in a Murine Model: An In Vivo Photobiomodulation Study[J]. Int J Med Sci, 2024, 21(15):2959-2973.
[43] Tenore G, Mohsen A, Del Vecchio A, et al.Surgical extraction with photobiomodulation as an adjunctive modality in patients at-risk for medication-related osteonecrosis of the jaw: retrospective study[J]. BMC Oral Health, 2025, 25(1):627.
[44] Park JH, Cho S, Kim SJ, et al.Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study[J]. Osteoporos Int, 2022, 33(2):367-377.
[45] Lorenzo-Pouso AI, Bravo SB, Carballo J, et al.Quantitative proteomics in medication-related osteonecrosis of the jaw: A proof-of-concept study[J]. Oral Dis, 2023, 29(5):2117-2129.
[46] Yang G, Singh S, McDonough CW, et al. Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw[J]. Clin Pharmacol Ther, 2021, 110(6):1558-1569.
[47] Lin H, Sohn J, Shen H, et al.Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing[J]. Biomaterials, 2019, 203:96-110.
[48] Tian RC, Zhang RY, Ma CF.Rejuvenation of Bone Marrow Mesenchymal Stem Cells: Mechanisms and Their Application in Senile Osteoporosis Treatment[J]. Biomolecules, 2025, 15(2):276.
[49] Voss PJ, Matsumoto A, Alvarado E, et al.Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells[J]. Odontology, 2017, 105(4): 484-493.
[50] 黄李蓉, 冯泽儒, 吴红崑, 等. 富血小板纤维蛋白促进骨再生效果的研究[J].中国口腔种植学杂志, 2025, 30(2):118-126.
[51] Dohan Ehrenfest DM, Rasmusson L, Albrektsson T.Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF)[J]. Trends Biotechnol, 2009, 27(3):158-167.
[52] Bouland C, Meuleman N, Widelec J, et al.Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF[J]. J Stomatol Oral Maxillofac Surg, 2021, 122(2):212-218.
[53] Zheng Y, Dong X, Wang X, et al.Exosomes Derived from Adipose Tissue-Derived Mesenchymal Stromal Cells Prevent Medication-Related Osteonecrosis of the Jaw through IL-1RA[J]. Int J Mol Sci, 2023, 24(10):8694.
[54] Zheng Y, Wang X, He Y, et al.Exosomes from Adipose-Derived Mesenchymal Stromal Cells Prevent Medication-Related Osteonecrosis of the Jaw by Inhibiting Macrophage M1 Polarization and Pyroptosis[J]. Int J Nanomedicine, 2024, 19:12675-12693.
[55] Dong X, Shen LH, Yi Z, et al.Exosomes from Adipose-Derived Stem Cells Can Prevent Medication-Related Osteonecrosis of the Jaw[J]. Med Sci Monit, 2021, 27: e929684.
[56] Ogata K, Katagiri W, Hibi H.Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro[J]. Clin Oral Investig, 2017, 21(6):1979-1988.

药物相关性颌骨坏死非手术治疗的研究进展

Research Advances in Non-Surgical Management of Medication-Related Osteonecrosis of the Jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	丁一辉, 王丹丹, 李晨璐, 王继弘, 田磊, 宗春琳. 特立帕肽在药物相关性颌骨坏死中治疗作用的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 297-306.
[2]	何金媛, 孙国文. 药物相关性颌骨坏死的机制及治疗研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 307-311.
[3]	徐冰玥, 鲁涵, 刘柯蓥, 何巍. 药物相关性颌骨坏死中微生态失衡的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 312-321.
[4]	江晨曦, 孙国文. 药物相关性颌骨坏死临床诊疗的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 331-336.
[5]	王睿, 孙国文. 3期药物相关性颌骨坏死的手术治疗的回顾性研究[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 345-352.
[6]	何金媛, 孙国文. 斜面导板改善下颌骨药物相关性颌骨坏死的咬合关系1例[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 360-366.
[7]	李娜, 常远, 高宁, 付坤, 蔡菁华, 高振杰, 乔翔鹤, 杨雷雷, 何巍. 药物相关性颌骨坏死的“互联网+”案例教学法的临床应用[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 367-374.